mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy

[1]  B. Autran,et al.  A truncated HIV Tat demonstrates potent and specific latency reversal activity , 2023, bioRxiv.

[2]  Ning Wang,et al.  A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis , 2023, Nature Communications.

[3]  Yihai Cao,et al.  The landscape of mRNA nanomedicine , 2022, Nature Medicine.

[4]  Zhongyu Li,et al.  Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines , 2022, ACS nano.

[5]  S. Leonov,et al.  Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer , 2022, Cell Death Discovery.

[6]  Zhongyu Li,et al.  Lipid‐Polymer Hybrid “Particle‐in‐Particle” Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID‐19 Vaccines , 2022, Advanced functional materials.

[7]  X. Ji,et al.  Transforming “cold” tumors into “hot” ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy , 2022, Matter.

[8]  J. Conde,et al.  Nanodelivery of nucleic acids , 2022, Nature Reviews Methods Primers.

[9]  One year of Methods Primers , 2022, Nature Reviews Methods Primers.

[10]  Jie Luo,et al.  Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment , 2021, Nature Communications.

[11]  Jordan A. Stinson,et al.  Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity , 2021, Nature Biomedical Engineering.

[12]  G. Nabel,et al.  Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models , 2021, Science Translational Medicine.

[13]  R. Langer,et al.  Lipid nanoparticles for mRNA delivery , 2021, Nature Reviews Materials.

[14]  T. Kanneganti,et al.  The 'cytokine storm': molecular mechanisms and therapeutic prospects. , 2021, Trends in immunology.

[15]  C. Bieberich,et al.  Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models , 2021, Science Translational Medicine.

[16]  Zhongyu Li,et al.  Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery , 2021, Advanced healthcare materials.

[17]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[18]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[19]  R. Webby,et al.  Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes , 2020, bioRxiv.

[20]  D. Irvine,et al.  Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity , 2020, Nature Cancer.

[21]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[22]  S. Ko,et al.  Messenger RNA/polymeric carrier nanoparticles for delivery of heme oxygenase-1 gene in the post-ischemic brain. , 2020, Biomaterials science.

[23]  L. Shen,et al.  Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells , 2020, Science.

[24]  S. Zheng,et al.  High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways , 2020, Signal Transduction and Targeted Therapy.

[25]  Huanwei Huang,et al.  A bioorthogonal system reveals antitumour immune function of pyroptosis , 2020, Nature.

[26]  J. Lieberman,et al.  Gasdermin E suppresses tumor growth by activating anti-tumor immunity , 2020, Nature.

[27]  Dongpei Li,et al.  Cancer immunotherapy: Pros, cons and beyond. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  L. Lei,et al.  The role of pyroptosis in cancer: pro-cancer or pro-“host”? , 2019, Cell Death & Disease.

[29]  Kyung Soo Park,et al.  Cancer nanomedicine for combination cancer immunotherapy , 2019, Nature Reviews Materials.

[30]  John D Lambris,et al.  Complementing the Cancer-Immunity Cycle , 2019, Front. Immunol..

[31]  Rachel S. Riley,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[32]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[33]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[34]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[35]  R. Gordon,et al.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer , 2017, Asia-Pacific journal of oncology nursing.

[36]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[37]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[38]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[39]  M. Lamkanfi,et al.  Pyroptosis , 2016, Current Biology.

[40]  Dacheng Wang,et al.  Pore-forming activity and structural autoinhibition of the gasdermin family , 2016, Nature.

[41]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[42]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[43]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[44]  J. Cui,et al.  Mechanisms and pathways of innate immune activation and regulation in health and cancer , 2014, Human vaccines & immunotherapeutics.

[45]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[46]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[47]  B. Cookson,et al.  Pyroptosis: host cell death and inflammation , 2009, Nature Reviews Microbiology.

[48]  G. C. Rogers,et al.  Culture of Drosophila S2 cells and their use for RNAi-mediated loss-of-function studies and immunofluorescence microscopy , 2008, Nature Protocols.

[49]  S. Ferrari,et al.  Author contributions , 2021 .

[50]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.